Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
J Clin Oncol. 2010 Apr 1;28(10):1666-70. doi: 10.1200/JCO.2009.23.5143. Epub 2010 Mar 1.
Accumulating evidence suggests that health-related quality of life (HRQL) data before treatment predict survival, but the prognostic value of changes in HRQL scores after treatment is unknown. The aim of this study was to explore whether changes in HRQL scores in esophagogastric cancer predict survival.
Consecutive patients undergoing curative treatment completed HRQL questionnaires (EORTC QLQ-C30) at baseline and after six months and were followed up for at least five years. Cox proportional hazard models with adjustments assessed associations between baseline HRQL and survival and between changes in HRQL before and after treatment and survival.
Overall, 216 patients initiated curative therapy, of whom 169 completed treatment and survived 6 months. Of these, 132 (7%) had two complete HRQL assessments. Analyses adjusted for age, sex, performance status, tumor stage, and disease site revealed that a 10-point poorer dyspnea score at baseline was significantly associated with an 18% higher risk of death. Additional analyses to adjust for baseline HRQL and treatment showed that a 10-point change in physical function (hazard ratio [HR], 0.85; 95% CI, 0.76 to 0.96; P = .007), pain (HR, 1.20; 95% CI, 1.09 to 1.33; P < .001), and fatigue (HR, 1.16; 95% CI, 1.04 to 1.30; P = .009) scores was associated with better survival.
This exploratory study found longer survival beyond the 6 months after starting treatment to be associated with fewer problems with dyspnea before treatment and better recovery of physical function, pain, and fatigue after treatment. More research to confirm these findings and understand the results is needed.
越来越多的证据表明,治疗前的健康相关生活质量(HRQL)数据可预测生存情况,但治疗后 HRQL 评分变化的预后价值尚不清楚。本研究旨在探讨胃食管交界癌患者 HRQL 评分变化是否可预测生存情况。
连续接受根治性治疗的患者在基线时和 6 个月后完成 HRQL 问卷(EORTC QLQ-C30),并至少随访 5 年。使用 Cox 比例风险模型进行调整,以评估基线 HRQL 与生存之间的相关性以及治疗前后 HRQL 变化与生存之间的相关性。
总体而言,有 216 例患者开始接受根治性治疗,其中 169 例完成了治疗并存活了 6 个月。在这些患者中,有 132 例(7%)完成了两次完整的 HRQL 评估。调整年龄、性别、体力状态、肿瘤分期和疾病部位后发现,基线时呼吸困难评分每降低 10 分,死亡风险就会增加 18%。进一步分析以调整基线 HRQL 和治疗后发现,体力功能(危险比 [HR],0.85;95%可信区间,0.76 至 0.96;P =.007)、疼痛(HR,1.20;95%可信区间,1.09 至 1.33;P <.001)和疲劳(HR,1.16;95%可信区间,1.04 至 1.30;P =.009)评分每改善 10 分,与生存时间延长相关。
这项探索性研究发现,开始治疗后 6 个月以上的生存时间延长与治疗前呼吸困难问题减少以及治疗后体力功能、疼痛和疲劳恢复更好相关。需要进一步的研究来证实这些发现并深入了解结果。